2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 792

Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate to Severe SLE
Abstract Number: 793

Multi-Parametric Model Development for Assessing Lupus Nephritis and Disease Activity
Abstract Number: 794

Development and Initial Validation of a Novel Lupus Disease Activity Index to Account for Glucocorticoids: Sledai-2K Glucocorticoids Index (SGI)
Abstract Number: 795

Low Disease Activity in Systemic Lupus Erythematosus: An Achievable Goal?
Abstract Number: 796

Establishment of an International Autoantibody Standard for Anti-DFS70/LEDGF Antibodies: Proof-of-Concept Study for a Novel Strategy for the Setting up of International Autoantibody Standards
Abstract Number: 797

Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations
Abstract Number: 798

Oxidized Phospholipids,Lipoprotein(a) and Glycosphingolipid Associated B-1,4 Galactosyltransferase in a Johns Hopkins Cohort of Patients with Systemic Lupus Erythematosus
Abstract Number: 799

Biomarker Identification & Molecular Sub-Classification in Systemic Sclerosis for Precision Medicine Using RNA-Seq
Abstract Number: 800

An Altered Cardiovascular System Development Gene Expression Signature in Skin is a Hallmark of Limited Cutaneous Systemic Sclerosis
Abstract Number: 801

Multi-Tissue Gene Expression Pathway Analysis of Emerging Therapeutics in a TGFβ Dependent Mouse Model of Systemic Sclerosis
Abstract Number: 802

Whole Transcriptome Profiling through RNA Sequencing Reveals Differentially Expressed Sense-Antisense Gene Pairs in Patients with Systemic Sclerosis
Abstract Number: 803

Multi-Organ RNA-Sequencing of Systemic Sclerosis (SSc) Patients Shows Reproducible Gene Expression Profiles Across Organ Systems
Abstract Number: 804

Combined-Phenotype Meta-GWAS in Systemic Sclerosis and Rheumatoid Arthritis Identifies IRF4 As a New Common Susceptibility Locus
Abstract Number: 805

HLA Class II Functional Motifs Associated with Severe Systemic Sclerosis (SSc) and Sclerotic Graft Versus Host Disease (sclGVHD): The Shared Epitopes of Fibrosis
Abstract Number: 806

Single Cell Rnaseq Defines a Unique Transcriptome Profile for Myofibroblasts in the Skin of Patients with Systemic Sclerosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].